-- DOXIL is an irritant, not a vesicant; use precautions to avoid
-- DOXIL can cause fetal harm when used during pregnancy
-- Recall reaction has occurred with DOXIL administration after
-- DOXIL may interact with drugs known to interact with the conventional
formulation of doxorubicin HCl
-- In patients with multiple myeloma, the most common all-grade ARs
greater than or equal to 20%
(VELCADE plus DOXIL vs VELCADE, respectively) included: neutropenia
(36% vs 22%), thrombocytopenia (33% vs 28%), anemia (25% vs 21%),
fatigue (36% vs 28%), pyrexia (31% vs 22%), asthenia (22% vs 18%),
nausea (48% vs 40%), diarrhea (46% vs 39%), vomiting (32% vs 22%),
constipation (31% vs 31%), mucositis/stomatitis (20% vs 5%), peripheral
neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash (22% vs 18%)
-- In addition, 19% vs <1% reported HFS Please see full Prescribing Information http://www.doxil.com/pdf/DOXIL_PI_Booklet.pdf, including Boxed WARNINGS.
DOXIL is marketed in the United States by Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX(R) throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit http://www.DOXIL.com.
VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium
is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag
is responsible for commercialization in Europe and the rest of the world.
Janssen Pharmaceutical K.K. is responsible for commercial
|SOURCE Ortho Biotech|
Copyright©2007 PR Newswire.
All rights reserved